Home
>
US Stocks
>
TALARIS THERAPEUTICS INC

TALARIS THERAPEUTICS INC (TALS)

$2.53

-0.01

(-0.39%)▲

Market is closed - opens 7 PM, 05 Jun 2023

Insights on TALARIS THERAPEUTICS INC

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 39.6% return, outperforming this stock by 110.8%

Performance

  • $2.43
    $2.63
    $2.53
    downward going graph

    3.95%

    Downside

    Day's Volatility :7.71%

    Upside

    3.92%

    downward going graph
  • $0.89
    $9.21
    $2.53
    downward going graph

    64.82%

    Downside

    52 Weeks Volatility :90.34%

    Upside

    72.53%

    downward going graph

Returns

PeriodTALARIS THERAPEUTICS INCSector (Health Care)Index (Russel 2000)
3 Months
28.43%
0.9%
-8.3%
6 Months
78.17%
-6.8%
-6.5%
1 Year
-71.05%
0.4%
-6.1%
3 Years
-81.18%
28.3%
21.8%

Highlights

Market Capitalization
110.0M
Book Value
$3.86
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.85
Wall Street Target Price
7.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-23.69%
Return On Equity TTM
-40.3%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-76.1M
Diluted Eps TTM
-1.85
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.99
EPS Estimate Next Year
-0.3
EPS Estimate Current Quarter
-0.49
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    63%Buy
    36%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for TALARIS THERAPEUTICS INC(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
8
8
Hold
4
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 196.44%

Current $2.53
Target $7.50

Technicals Summary

Sell

Neutral

Buy

TALARIS THERAPEUTICS INC is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
TALARIS THERAPEUTICS INC
TALARIS THERAPEUTICS INC
-11.54%
78.17%
-71.05%
-81.18%
-81.18%
Moderna, Inc.
Moderna, Inc.
-2.84%
-25.82%
-6.78%
115.4%
601.67%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.85%
-2.05%
21.5%
23.63%
137.1%
Seagen, Inc.
Seagen, Inc.
-1.57%
61.18%
37.09%
29.88%
217.64%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.7%
5.09%
24.54%
22.34%
123.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
TALARIS THERAPEUTICS INC
TALARIS THERAPEUTICS INC
NA
NA
NA
-0.99
-0.4
-0.24
0.0
3.86
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.91
19.91
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.18
26.18
0.41
14.61
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
TALARIS THERAPEUTICS INC
TALARIS THERAPEUTICS INC
Buy
$110.0M
-81.18%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
601.67%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$80.7B
137.1%
19.91
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.5B
217.64%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.3B
123.04%
26.18
35.4%

Institutional Holdings

  • Blackstone Inc

    18.70%

  • Citadel Advisors Llc

    8.14%

  • Viking Global Investors LP

    7.60%

  • Qiming U.S. Ventures Management, LLC

    6.78%

  • BML Capital Management LLC

    4.46%

  • Eventide Asset Management, LLC

    3.61%

Corporate Announcements

  • TALARIS THERAPEUTICS INC Earnings

    TALARIS THERAPEUTICS INC’s price-to-earnings ratio stands at None

    Read More

Company Information

Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders. Talaris maintains corporate offices in Boston, Mass., and its cell processing facility in Louisville, Ky.

Organization
TALARIS THERAPEUTICS INC
Employees
84
CEO
Mr. Scott Requadt J.D., L.L.B., M.B.A., MBA
Industry
Healthcare

Discover More

FAQs